Targeting neoantigens to APC- surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine

In this study, we demonstrate how the addition of an antigen-presenting cell (APC) binding molecule to DNA-encoded cancer neoepitopes improves neoepitope-specific T-cell responses and the anti-tumor efficacy of plasmid DNA vaccines. Dose-response evaluation and longitudinal analysis of neoepitope-specific T-cell responses indicate that combining APC-binding molecules with the delivery of personalized tumor antigens holds the potential to improve the clinical efficacy of therapeutic DNA cancer vaccines.

Publication: Frontiers in Immunology

By: Evaxion & Nature Research Custom Media